摘要
目的:探讨持续性躯体形式疼痛障碍采用氟西汀、度洛西汀治疗的临床对比。方法:选择2009年3月-2012年1月笔者所在医院收治的持续性躯体形式疼痛障碍患者80例,随机分为两组,对照组40例采用氟西汀治疗,观察组40例采用度洛西汀治疗,就两组临床资料进行回顾性分析。结果:两组治疗后2周、4周、6周HAMD评分比较差异无统计学意义(P>0.05)。两组治疗后不同阶段MOSPM完全缓解率比较差异无统计学意义(P>0.05)。观察组治疗后2周、4周TESS评分情况均低于对照组(P<0.05),两组6周TESS评分情况比较差异无统计学意义(P>0.05)。观察组不良反应发生率明显低于对照组(P<0.05),均经对症处理后好转。结论:持续性躯体形式疼痛障碍采用度洛西汀及氟西汀治疗在效果上无明显差异,但度洛西汀不良反应较少,可显著提高患者的用药依从性。
Objective ： To investigate the clinical comparison of the persistent somatoform pain disorder with fluoxetine, duloxetine treatment.Methods ： 80 cases patients with persistent somatoform pain disorder were sdected in author＇s hospital from March 2009 to January 2012, divided into two groups randomly, 40 cases in the control group were treaded with fiuoxetine, 40 cases in observalion growp were treated with duloxetine, the clinical data of two groups were retrospectively analyzed.Results ： The HAMD scores of two groups after treatment of 2 weeks, 4 weeks, 6 weeks showed no significant difference, the difference was not statistically significant（P〉0.05）.The difference was not statistically significant in the MOSPM complete remission rate of two groups after treatment with different stages（P〉0.05）.The ratings of the observation group after 2 weeks of treatment, 4 week were lower than the control group （P〈0.05）.6 week grading of two groups showed no significant difference（P〉0.05）.In observation group, the incidence of adverse reactions were significantly lower than the control group（P〈0.05）.All the symptom improved after treatment.Conclusion ： Persistent somatoform pain disorder with duloxetine and fluoxetine treatment in effect have no significant difference, but the duloxetine adverse to be less, can significantly improve patient compliance.
出处
《中外医学研究》
2012年第31期1-2,共2页
CHINESE AND FOREIGN MEDICAL RESEARCH
